



### CONTACT US:

**Brian B. Berger, MD**  
[bberger@e-retina.net](mailto:bberger@e-retina.net)

**Ginger Manhart**  
[gmanhart@e-retina.net](mailto:gmanhart@e-retina.net)  
512-279-1250

- **Allergan REACH**
- **Quark MATISSE**
- **Pfizer NAION**
- **DRCR**
- **XOMA**

**Ivana Gunderson**  
[igunderson@e-retina.net](mailto:igunderson@e-retina.net)  
512-279-1251


- **Pfizer B1181003**
- **GSK BAM114341**
- **iDEAL**

**Tori Moore**  
[tmoore@e-retina.net](mailto:tmoore@e-retina.net)  
512-454-0138

## Ultrawide Field Imaging

In the recent issue of *American Journal of Ophthalmology*, Joslin Diabetes Center reported that OPTOS 200 degree ultrawide field imaging is comparable to Early Treatment Diabetic Retinopathy Study (ETDRS) gold standard seven field stereoscopic fundus photography in determining clinical severity of diabetic retinopathy and diabetic macular edema. The ultrawide field advantages include capture in less than half the time of dilated images, easier operation, and no pupil dilation.

Dr. Berger is currently using ultrawide field imaging in his office to evaluate diabetic retinopathy and appreciates the advantages that this new technology has to offer. 200 degree imaging can be obtained with one capture which translates to greater patient comfort. Furthermore, the patients and the doctor are better able to appreciate the impact of disease by observing one complete view of the eye.



Ultra wide view of treated choroidal melanoma

Additionally, Dr. Berger finds this technology particularly helpful in the management of ocular melanomas. Rather than relying on a montage, ultrawide field imaging captures the full range of the tumor in one image.



## Retina Research Center offers two novel therapeutic approaches for Diabetic Macular Edema

iCo Therapeutics, [www.icotherapeutics.com](http://www.icotherapeutics.com), is developing Co-007 a second generation antisense inhibitor targeting C-raf kinase messenger ribonucleic acid (mRNA). iCo-007's works by reducing expression of C-raf kinase to block both growth factor and Integrin-mediated signal transduction, thus inhibiting both vascular permeability and angiogenic processes. This strategy has the potential to block the signaling of multiple growth factors, and to inhibit both cellular activation and differentiation processes; consequently, this new mechanism might prove a more robust treatment for diabetic macular edema. To date, Retina Research Center has randomized and treated 7 patients



Quark Pharmaceutical, Inc., [www.quarkpharma.com](http://www.quarkpharma.com), is developing PF-04523655, a small interfering ribonucleic acid (siRNA), designed to temporarily inhibit the expression of the hypoxia-inducible gene, RTP801, via activation of the RNA interference (RNAi) pathway. This trial is a follow-up to the DEGAS study conducted by Pfizer, Inc. which showed a positive correlation between dose levels and the improvement in BCVA change from baseline with a maximum dose tested of 3mg. Quark is examining the 3mg - 12mg doses of PF-04523655 in this clinical trial.

	<b>iDEAL</b>	<b>Matisse (QUARK)</b>
<b>Duration</b>	12 months	6 months
<b>Visit Frequency</b>	q1 month	q1 month
<b>Treatment Interval</b>	q4 months	q1 month
<b>Randomization</b>	1:1:1:1	1:1
<b>BCVA (Study Eye)</b>	20/32-20/320	20-40-20/320
<b>BCVA (Fellow Eye)</b>	none	20/400 or better
<b>Edema on OCT</b>	≥ 250μ Stratus	≥ 340μ Spectralis
<b>Focal Laser wash out</b>	3 months	3 months
<b>PRP wash out</b>	3 months	6 months
<b>IVI Steroids wash out</b>	3 months	3 months
<b>IVI VEGF-F wash out</b>	2 months	3 months
<b>Compensation</b>	\$30 per visit	\$25 per visit
<b>Transportation</b>	NO	YES

## **Enrolling Trials:**

### **Wet Age-Related Macular Degeneration**

**Allergan REACH** - Single and repeat dose study of the safety and efficacy of AGN-150998 in patients with treatment naïve exudative age-related macular degeneration.

### **Dry Age-Related Macular Degeneration**

**GSK BAM114341** - A phase II study of GSK933776, a monoclonal antibody, in adult patients with geographic atrophy (GA) secondary to age-related macular degeneration.

**Pfizer B1181003** - A Phase II study evaluating RN6G (monoclonal antibody binding amyloid beta) in subjects with geographic atrophy (GA) secondary to age-related macular degeneration.

### **Uveitis**

**XOMA X052130/ CL3-78989-005** - A study of monthly subcutaneous injections of gevokizumab in the treatment of active non-infectious intermediate, posterior, or pan-uveitis

### **Diabetic Macular Edema**

**iCO Therapeutics and Juvenile Diabetes Foundation (iDEAL Study)** - A Phase II study of repeated intravitreal injections of iCO-007 as monotherapy or in combination with ranibizumab or laser photocoagulation in the treatment of diabetic macular edema with involvement of foveal center.

**Quark QRK202 (Matisse)** - An open-label dose escalation study of PF-04523655 alone and in combination with ranibizumab versus ranibizumab alone in diabetic macular edema.

**DRCR S**—Prompt panretinal photocoagulation versus intravitreal ranibizumab with deferred panretinal photocoagulation for proliferative diabetic retinopathy

## **Presentations & Publications**

- ▶ “Fluocinolone Implant for Idiopathic Non-Infectious Posterior Uveitis,” *Retina Physician*, May 2012, pages: 2-6
- ▶ “Sclerotomy Closure for Retisert Implant,” to be presented at The Retina Society 2012 Annual Meeting, Washington D.C.; October 2012
- ▶ Breakfast with the experts, “Key Diagnostic Signs in Posterior Uveitis,” American Academy of Ophthalmology, Chicago, IL; November 2012

## **University of Chicago Student Volunteer**



Retina Research Center is pleased to have Anisha Gauguly joining us this summer from the University of Chicago. She is a pre-medical student with concentrations in biochemistry and Spanish.

Anisha, is a graduate of Westlake high school and a great contributor to our team.